Panelists discuss how detailed analyses from KarMMa-3 reveal key insights about ide-cel’s performance across patient subgroups, timing of responses, durability of remissions, and management of adverse ...

Patients with RA who have used b/tsDMARDs demonstrated similar risks for multiple myeloma when compared with those taking only csDMARDs.

Karyopharm Therapeutics Inc.’s KPTI share price has surged by 10.77%, which has investors questioning if this is right time to sell.

We believe Genmab is in solid financial health. At the end of 2024, Genmab held DKK 9.9 billion in cash and cash equivalents. After turning profitable in 2013, the company has steadily increased its ...

Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.

According to the agency, the 15-year-old company only presented efficacy claims for its branded medication and did not include any warnings or precautions for the tablets at a tradeshow.

New treatments for graft-vs.-host disease, updated dosage for HPV vaccines — and Fred Hutch announces awards for graduate students.

An elderly patient who was initially suspected of having antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) was instead diagnosed with multiple myeloma, according to a case report ...

The FDA has sent its first untitled letter of 2025, hitting Edenbridge Pharmaceuticals with a notice after assessin | The FDA ...

The Health, Hope and Hip Hop Foundation made history this February, hosting its first-ever "Hip Hope Ball: A Celebration to Ignite Change" on the final ...

More than three decades after the EPA added Fort Ord to its list of most contaminated places, the former base is still being ...

More than three decades after the EPA added Fort Ord to its list of most contaminated places, the former base is still being ...